Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Original Article

T.K. Choueiri, T. Powles, K. Peltola, G.d. Velasco, M. Burotto, C. Suarez, P. Ghatalia, R. Iacovelli, E.T. Lam, E. Verzoni, M. Gümüş, W.M. Stadler, C. Kollmannsberger, B. Melichar, B. Venugopal, M. Gross-Goupil, A. Poprach, M.D. Santis, F.A. Schutz, S.H. Park, D.A. Nosov, C. Porta, J.L. Lee, X. Garcia-del-Muro, E. Biscaldi, R.M. Kopp, M. Oya, L. He, A. Wang, R.F. Perini, D. Vickery, L. Albiges, and B. Rini

N Engl J Med 2024;391:710-721

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
08/21/2024
Course expires: 
08/22/2026

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.